Sakditad Saowapa, Oncologist at UI Holden Comprehensive Cancer Center, shared a post on X:
“ISTH 2025 Highlights.
Learned so much from the session “Thrombopoietin: A journey from bench to bedside” moderated by Dr. Manuel Carcao!
Key takeaways on TPO/TPO-RAs:
- Role in CIT (Chemotherapy-Induced Thrombocytopenia)
- Applications in AML, MDS, stem cell collection, liver disease, HCV
- Emerging use of Hetrombopag
- Improved platelet recovery
- Reduced chemo delays
- Higher dose intensity
Trials showed romiplostim and hetrombopag may significantly impact outcomes by preventing dose reductions and delays.
NCCN 2025 CIT guideline highlights:
- Consider TPO-RA in platelet <100K for ≥3–4 weeks post-chemo
- Romiplostim: 2–10 mcg/kg/week
Impressive science, powerful clinical relevance.”
More posts featuring Sakditad “Tew” Saowapa.